Baicalin nanoengineered probiotics synergistically suppress IL-6/STAT3 signaling and remodel gut microbiota for Crohn’s disease therapy

Junru Wang, Xia Zhang, Pengyu Chen, Pandi Peng, Chaofan Nie, Luofeng Yu, Yang Liu, P. Wang, Tao Feng, Peng LiNano 2025 · DOI

TL;DR

Researchers have developed a "nanoengineered probiotic" by coating Escherichia coli Nissle 1917 (EcN) with a metal-phenolic network composed of ferric ions, baicalin, and tannic acid. This protective "armor" significantly enhances probiotic survival through the stomach while synergistically suppressing the IL-6/STAT3 inflammatory pathway and restoring gut microbial balance in Crohn’s disease models.

What Problem Does This Paper Address?

Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by a "vicious cycle" of transmural inflammation, intestinal barrier breakdown, and gut microbiota dysbiosis. While probiotics offer a promising therapeutic avenue, they face two major hurdles:

  1. Low Survival: Most probiotics are decimated by the harsh acidic environment of the stomach before they reach the colon.
  2. Limited Efficacy: Standard probiotics often lack the multi-pronged potency needed to tackle the complex molecular signaling (like the IL-6/STAT3 axis) that drives CD.

Furthermore, natural bioactive molecules like Baicalin (BA) have excellent anti-inflammatory properties but suffer from poor solubility and low oral bioavailability. The authors sought to create a "microecologic" that protects the probiotic and uses it as a vehicle to deliver BA directly to the site of inflammation.

Methods

The authors developed Fe-BT@EcN, a hybrid system created through coordination-driven self-assembly:

  • Nanoengineering: They coated the probiotic E. coli Nissle 1917 with a metal-phenolic network (MPN) consisting of Ferric ions ($Fe^{3+}$), Baicalin (BA), and Tannic Acid (TA).
  • Network Pharmacology & Docking: To understand why Baicalin works, they used computational tools to map 2,035 CD-related targets and 257 BA-related targets, identifying 78 common intersections. Molecular docking was used to simulate the binding affinity of BA to the STAT3 protein.
  • In Vivo Modeling: They used a murine model where CD was induced using 2,4,6-trinitrobenzenesulfonic acid (TNBS).
  • Microbiota Analysis: 16S rRNA gene sequencing was performed to track changes in the gut bacterial ecosystem after treatment.

Datasets

The study relied on several bioinformatics and structural databases for its computational analysis:

  • Disease/Drug Targets: DrugBank, TTD, DisGeNET, GeneCards, OMIM, and PharmGKB.
  • BA Target Prediction: Swiss Target Prediction, STITCH, PharmMapper, CTD, and TCMSP.
  • Protein Interactions: The STRING database was used to construct protein-protein interaction (PPI) networks.
  • Microbiota Annotation: The SILVA reference database was used for taxonomical annotation of sequencing data.

Key Insights and Ideas

  • The "Survival Suit": The MPN coating acts as a robust shield. While naked EcN was completely inactivated in simulated gastric fluid (SGF) within 60 minutes, the nanoengineered version showed an 18.30-fold higher survival rate.
  • Precision Anti-Inflammation: Network pharmacology revealed that Baicalin isn't just a generic antioxidant; it specifically targets the IL-6/STAT3 signaling pathway. By inhibiting the phosphorylation of STAT3, it prevents the transcription of pro-inflammatory cytokines that exacerbate CD.
  • Synergistic Remodeling: The treatment doesn't just kill "bad" bacteria; it rebalances the ecosystem. It significantly increased the abundance of beneficial Firmicutes while reducing harmful groups like Coriobacteriaceae_UCG-002 and Erysipelotrichaceae, which are known to aggravate intestinal permeability.
  • Enhanced Adhesion: The phenolic coating improved the mucoadhesive properties of the bacteria, allowing them to colonize the colon more effectively than uncoated probiotics.

Key Results

  • Clinical Recovery: In the TNBS mouse model, Fe-BT@EcN treatment led to a 21.3% increase in body weight and a 67.2% reduction in the Disease Activity Index (DAI) compared to untreated CD mice.
  • Tissue Integrity: Treated mice showed a 22.3% prolongation in colonic length (indicating reduced inflammation-induced shrinkage) and significant restoration of tight junction proteins like ZO-1 and Occludin.
  • Molecular Suppression: Immunofluorescence confirmed a significant reduction in IL-6 expression and a 32.4% decrease in p-STAT3 levels in the colon tissue.
  • Microbial Diversity: Treatment restored the Shannon diversity index and increased the number of observed operational taxonomic units (OTUs), moving the gut profile closer to that of healthy control mice.

Limitations and Future Work

While the results are promising, the authors and the context of the field suggest some areas for further exploration:

  • Model Specificity: The TNBS-induced model is a chemical injury model; while it mimics many features of CD, it does not fully replicate the chronic, relapsing-remitting nature of human autoimmune Crohn's disease.
  • Long-term Safety: While the components (Fe, BA, TA, EcN) are generally considered safe, the long-term metabolic fate of the metal-phenolic coating in a chronically inflamed gut requires further longitudinal study.
  • Translational Scale: The preparation involves precise vortex mixing and coordination; scaling this up to industrial pharmaceutical manufacturing while maintaining coating uniformity will be a key engineering challenge.

Summary updated

Abstract

Crohn’s disease (CD) is chronic inflammatory bowel disorder characterized by transmural inflammation, intestinal barrier disruption, and gut microbiota dysbiosis. Although probiotics show therapeutic potential for CD through modulating the intestinal flora, conventional oral formulations are constrained by low survival rates in the gastrointestinal tract and limited efficacy. Inspired by the metal-coordinating property and anti-inflammatory effect of baicalin (BA), the nanoengineered probiotics Fe-BT@EcN are developed through synergy with tannic acid and ferric ions, demonstrating enhanced resistance to adverse gastric environment as well as improved intestinal adhesion and colonization. Notably, as confirmed by network pharmacology and molecular docking studies, BA targets dual therapeutic pathways in CD intervention to elevate antioxidant and anti-inflammatory activities through regulation of reactive oxygen species (ROS) levels and inhibition of the IL-6/STAT3 signaling pathway. In a murine 2,4,6-trinitrobenzenesulfonic acid (TNBS) induced CD model, Fe-BT@EcN exhibited synergistic therapeutic efficacy by alleviating colonic inflammation, restoring epithelial barrier function, and reestablishing microbial homeostasis. This study provides a feasible strategy to develop multifunctional oral microecologics for CD treatment through leveraging different probiotics and natural bioactive small molecules.
BibTeX
@inproceedings{wang2025baicalin,
  author = {Junru Wang and Xia Zhang and Pengyu Chen and Pandi Peng and Chaofan Nie and Luofeng Yu and Yang Liu and P. Wang and Tao Feng and Peng Li},
  title = {{Baicalin nanoengineered probiotics synergistically suppress IL-6/STAT3 signaling and remodel gut microbiota for Crohn’s disease therapy}},
  booktitle = {Nano},
  year = {2025},
  doi = {10.26599/nr.2026.94908355},
}
Figure